<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The presence of <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> clones in the setting of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> has been shown to have prognostic and therapeutic implications </plain></SENT>
<SENT sid="1" pm="."><plain>However, the status of <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> clones in various categories of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and in other <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorders</z:e> is not well-studied </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: By using multiparameter flow cytometry immunophenotypic analysis with antibodies specific for four <z:chebi fb="0" ids="24410">glycosylphosphatidylinositol</z:chebi>-anchored proteins (CD55, CD59, CD16, CD66b) and performing an aerolysin lysis confirmatory test in representative cases, we assessed the <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo>-phenotype granulocytes in 110 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, 15 with myelodysplastic/<z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath>, 5 with idiopathic <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> and 6 with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:hpo ids='HP_0004818'>Paroxysmal nocturnal hemoglobinuria</z:hpo>-phenotype granulocytes were detected in nine patients with low grade <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> who showed clinicopathological features of <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo>, similar to <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo>-positive cases demonstrated loss of the four <z:chebi fb="0" ids="24410">glycosylphosphatidylinositol</z:chebi>-anchored proteins, with CD16(-)CD66b(-) clones being larger than those of CD55(-)CD59(-) (p&lt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Altered <z:chebi fb="0" ids="24410">glycosylphosphatidylinositol</z:chebi>-anchored protein expression secondary to granulocytic hypogranulation, immaturity, and/or immunophenotypic abnormalities was present in a substantial number of cases and diagnostically challenging </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: These results show that routine screening for <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> clones in patients with an intrinsic <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disease</z:e> who show no clinical evidence of <z:mp ids='MP_0010163'>hemolysis</z:mp> has an appreciable yield in patients with low grade <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The recognition of diagnostic caveats and pitfalls associated with the underlying intrinsic <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disease</z:e> is essential in interpreting <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> testing correctly </plain></SENT>
<SENT sid="8" pm="."><plain>In our experience, the CD16/CD66b antibody combination is superior to CD55/CD59 in screening for subclinical <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> because it detects a large clone size and is less subject to analytical interference </plain></SENT>
</text></document>